Agreements reached under this partnership
Business alliance- 1
Promotes the research and development of new functional materials and supports their expansion into the Japanese market by leveraging its research and development platform.
- 2
Acts as the liaison between Kelun Yongnian and the SOKEN Holdings Group, handling communication between Japan and China and coordinating the project.
- 3
The SOKEN Holdings Group will establish scientific evidence through clinical research and functional evaluation in Japan and promote the commercialization and business development of products in the Japanese market.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
We believe that advancing research and development and commercialization under this agreement will contribute to improvements in our business performance and corporate value over the medium term. The impact on performance for the current fiscal year is currently under review.
| Item | Details |
|---|---|
| Name of alliance partner | Kelun Yongnian Health Industry Co., Ltd., Siniti Biotechnology Co., Ltd. |
| Alliance partner's business activities | Engages in the research and development and commercialization of new food and health-food ingredients., Focuses on the pharmaceutical field between Japan and China, supports Chinese pharmaceutical companies' entry into the Japanese market, and promotes the research and development of new drugs. |
| Alliance partner's location | China |
| Type of alliance | Business alliance |
| Details of the alliance | Promotes the research and development of new functional materials and supports their expansion into the Japanese market by leveraging its research and development platform., Acts as the liaison between Kelun Yongnian and the SOKEN Holdings Group, handling communication between Japan and China and coordinating the project., The SOKEN Holdings Group will establish scientific evidence through clinical research and functional evaluation in Japan and promote the commercialization and business development of products in the Japanese market. |
| Impact on Business Performance | We believe that advancing research and development and commercialization under this agreement will contribute to improvements in our business performance and corporate value over the medium term. The impact on performance for the current fiscal year is currently under review. |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To promote the commercialization of new functional materials by combining Sichuan Kelun Pharmaceutical Group's research, development and manufacturing capabilities with the SOKEN Holdings Group's expertise in clinical research, functional evaluation and the establishment of scientific evidence in Japan.